Complix Announces Expanded Strategic Oncology Collaboration with MSD to Develop Cell-Penetrating Alphabodies

Complix, a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies™, for the treatment of cancer and severe autoimmune diseases, announced today that MSD (also known as Merck & Co., Inc., Kenilworth, NJ., USA, in the United States and Canada),...

Continue reading at Edmond de Rothschild →